IL31 and Alzheimer disease: Consistent with a role for IL‐31 in itch, a phase 2 trial of nemolizumab, a humanised antibody targeting IL‐31 receptor A, demonstrated significant itch reduction in patients with moderate‐to‐severe AD.36